Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Zentalis Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Zentalis Pharmaceuticals, Inc.

ZNTL

Zentalis Pharmaceuticals, Inc.

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, notably azenosertib, a WEE1 inhibitor. The company’s primary market includes ovarian and other solid tumors, with a focus on biomarker-driven treatments for unmet medical needs. Its business model emphasizes innovative drug development, strategic collaborations, and reliance on third-party manufacturing to bring potentially first-in-class therapies to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Zentalis Pharmaceuticals, Inc.

1
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports $35.4 Million Net Loss in Q1 2026, Announces Phase 3 Trial for Azenosertib

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports $137.1 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports Improved Net Loss of $26.7 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports $26.9 Million Net Loss in Q2 2025, Improved from Previous Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports $48.3 Million Net Loss Amid Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports $165.9 Million Net Loss, First Revenue of $67.4 Million in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals Reports Improved Financial Results, Reduced Losses, and Increased Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments